Genmab A/ S stock (DK0010272202): cancer drug specialist updates outlook after recent earnings

Genmab A/S has reported fresh quarterly figures and updated its guidance, while its oncology partnerships with big pharma remain in focus for investors following the latest market reaction to the stock.

Genmab A/S has remained in the spotlight after publishing its latest quarterly results and updating its full-year guidance, with markets weighing continued revenue growth from key oncology antibodies such as Darzalex and Tivdak against rising R&D spending, according to a results release dated 05/08/2026 on the company’s investor relations site Genmab IR as of 05/08/2026 and a subsequent coverage report from Reuters as of 05/09/2026.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Genmab
• Sector/industry: Biotechnology, oncology therapeutics
• Headquarters/country: Copenhagen, Denmark
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Oncology antibodies, partnered drug royalties and milestones
• Home exchange/listing venue: Nasdaq Copenhagen (GMAB), Nasdaq Global Select Market (GMAB)
• Trading currency: Danish krone on Copenhagen, US dollar on Nasdaq

Genmab A/S: core business model

Genmab A/S focuses on discovering and developing antibody-based medicines, primarily in oncology. Its model combines proprietary antibody technologies with a partnership-driven approach, collaborating with larger pharmaceutical companies that handle parts of development, manufacturing, and commercialization in exchange for milestones and royalties, according to its company description published with the 2025 annual report on 02/21/2026 on Genmab corporate site as of 02/21/2026.

This setup allows Genmab to maintain a relatively focused internal organization while leveraging the global sales and regulatory infrastructure of partners such as Johnson & Johnson and Pfizer for key assets. The company also advances a number of wholly owned or co-owned candidates in-house, particularly in early and mid-stage clinical development, before assessing whether to seek additional partners or retain more commercial rights, according to its pipeline overview updated on 03/15/2026 on Genmab IR as of 03/15/2026.

In recent years the company has broadened its focus beyond traditional monoclonal antibodies toward bispecific antibodies and antibody-drug conjugates (ADCs), aiming to address hematologic malignancies and solid tumors with more targeted approaches. The combination of platform technologies, a diversified pipeline, and income from marketed products gives Genmab a hybrid profile, blending characteristics of a commercial-stage biotech with those of a research-focused platform company.

Main revenue and product drivers for Genmab A/S

The main revenue driver for Genmab remains Darzalex, an anti-CD38 monoclonal antibody for multiple myeloma developed in partnership with Johnson & Johnson. Genmab receives royalties and certain milestone payments from global sales of Darzalex, which continued to grow year over year in the latest reported quarter, according to the Q1 2026 earnings release dated 05/08/2026 on Genmab IR as of 05/08/2026.

Beyond Darzalex, Genmab earns significant revenue from technologies used in other partnered medicines and from its own marketed products such as Tivdak, a tissue factor-directed ADC for recurrent or metastatic cervical cancer. Tivdak is co-developed and co-commercialized with Pfizer, and the product’s uptake in the United States has been highlighted as a growth contributor, according to a product update included in the same Q1 2026 presentation on Genmab IR as of 05/08/2026.

The company’s revenue mix also includes milestone payments tied to clinical and regulatory progress of partner-led programs. In the first quarter of 2026, Genmab reported total revenue of approximately DKK 4.3 billion for Q1 2026, up from around DKK 3.6 billion in Q1 2025, reflecting continued strength in Darzalex royalties and higher collaboration revenue, according to the Q1 2026 financial report published 05/08/2026 on Genmab IR as of 05/08/2026.

Operating expenses, however, also increased due to expanded R&D activities and higher selling, general, and administrative costs linked to Genmab’s growing commercial infrastructure. As a result, operating income for Q1 2026 came in at roughly DKK 1.3 billion versus about DKK 1.1 billion a year earlier, maintaining profitability but highlighting the balance between reinvestment in the pipeline and near-term earnings, according to the same Q1 2026 report on Genmab IR as of 05/08/2026.

Industry trends and competitive position

Genmab operates in a highly competitive oncology biologics market that includes large pharmaceutical companies and specialized biotech peers. Demand for targeted cancer therapies and immunotherapies continues to grow, supported by demographic trends and expanding indications, according to an oncology market outlook published on 04/10/2026 by IQVIA as of 04/10/2026. Within this context, Genmab’s antibody platforms and established partnerships provide it with visibility in major treatment segments.

The company’s collaboration model allows it to compete effectively despite not having the scale of big pharma, as partners such as Johnson & Johnson and Pfizer deploy global sales teams to promote shared products. At the same time, Genmab’s internal pipeline investments in bispecific antibodies and ADCs reflect industry trends where combination regimens and more precise targeting are gaining momentum, according to a sector analysis released 03/29/2026 by S&P Global Market Intelligence as of 03/29/2026.

Competition remains intense in multiple myeloma, cervical cancer, and other target indications, so clinical differentiation and safety profiles remain critical for long-term revenue potential. Genmab’s multi-asset portfolio partly mitigates single-product risk but also requires ongoing substantial R&D investment, which can influence profitability across economic cycles and shifts in healthcare reimbursement, especially in the United States and Europe.

Why Genmab A/S matters for US investors

For US investors, Genmab is accessible both via its American listing on the Nasdaq Global Select Market under the ticker GMAB and through its role as a partner in key oncology drugs widely prescribed in the US healthcare system. Darzalex, for example, is an established treatment for multiple myeloma in the United States, and Tivdak is marketed for cervical cancer in the US, which ties Genmab’s royalty and collaboration income closely to US oncology drug spending, according to prescribing and sales data referenced in the company’s 2025 annual report dated 02/21/2026 on Genmab IR as of 02/21/2026.

US-based investors may also follow Genmab as part of the broader biotech and pharmaceutical ecosystem, where cross-border partnerships are common and valuation can be influenced by clinical trial readouts, regulatory decisions from the US Food and Drug Administration, and reimbursement developments under Medicare and private insurers. The company’s dual listing and reporting in both Danish kroner and US dollars contribute to its visibility among international institutional investors, several of which are headquartered in the United States, according to the shareholder information updated 03/20/2026 on Genmab IR as of 03/20/2026.

In addition, Genmab’s research and development collaborations with US biotech firms and academic institutions form part of a broader innovation network that could yield new assets for partnering or commercialization in the American market. This exposure gives the stock sensitivity to trends in US capital markets, such as risk appetite for growth-oriented healthcare names and regulatory shifts that affect drug pricing and approval timelines.

Conclusion

Genmab A/S stands out as a specialized oncology player that combines a partnered commercial franchise with an expanding pipeline of antibody-based therapies. Recent quarterly results confirmed ongoing revenue growth from flagship products like Darzalex and Tivdak, while also highlighting rising R&D costs as the company invests in next-generation platforms and clinical programs. For US-focused investors, Genmab’s Nasdaq listing, direct exposure to the US oncology market through key products, and collaboration-driven business model make it a notable name in the biotech segment, though outcomes for the share price will continue to depend on clinical, regulatory, and competitive developments as well as broader risk sentiment in global equity markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.